Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab

Allergy. 2020 Apr;75(4):940-942. doi: 10.1111/all.14035. Epub 2019 Oct 3.

Authors

Luis A Pérez de Llano¹, David Dacal Rivas¹, Borja G Cosío^{2

3}

Affiliations

¹ Pneumology Service, Hospital Universitario Lucus Agusti, EOXI Lugo, Cervo, Monforte, Spain.
² Department of Respiratory Medicine, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Mallorca, Spain.
³ CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

PMID: 31483864
DOI: 10.1111/all.14035

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Humans
Omalizumab / therapeutic use

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Omalizumab
reslizumab
mepolizumab